Iovance Biotherapeutics

1 follower

Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.






Org chart

Frederick G. Vogt
Interim CEO, President & General Counsel

Frederick G. Vogt

Friedrich Graf Finckenstein
Chief Medical Officer
Howard B. Johnson
Chief Business Officer
Jim Ziegler
EVP, Commercial
Brian Shew
SVP, Head of Digital & Information Technology
Tracy Winton
SVP, Human Resources
Kevin Smyth
SVP, Quality
Hequn Yin
SVP, Research
Ahmed Tawashi
Vice President, Research Alliances
Jessica Reckner
Senior Director Of Marketing
Nicholas Rojeski
Executive Director, US Marketing
Z. Dale He
US Oncology Cell Therapy Marketing Director
Mariam Mirgoli
Senior Vice President, Data Management And Solutions
Jim Kirk
Director Quality Compliance
Renee Doggett
Director, Quality Control Compliance
Stefanie Bulilan
Sr. Director Quality Systems And Compliance
Asq Cqa Ulises Villavicencio
Associate Director, QA Compliance
Sean Rocca
Executive Counsel
Joseph Yglesias
Manager, Next Generation Sequencing